Driving End-to-End Success in Cell Therapy: Automated, Modular Solutions for Autologous and Allogeneic Workflows
Workshop: Join industry leaders for an engaging panel discussion exploring the future of end-to-end cell therapy manufacturing. This session will examine how next-generation automation, modular platforms, and flexible workflows are shaping both autologous and allogeneic therapeutic development. Panelists will discuss the evolving challenges across the manufacturing ecosystem—from early-stage process development to clinical and commercial scale—and share perspectives on where innovation is most needed to drive quality, consistency, and patient access.
What to Expect
- Insight into Thermo Fisher Scientific’s latest innovations, including:
- Gibco™ Dynabeads™ CD3 Depletion Prototype
- Gibco™ CTS™ Compleo™ Fill and Finishing System (coming soon!)
- Examples of how advanced, integrated tools enable streamlined, scalable, and closed cell therapy processes.
- A solution-agnostic discussion that stays focused on broad industry needs, trends, and recommended practices.
- Real-world perspectives from experts on challenges and opportunities across both autologous and allogeneic workflows.
- Practical takeaways on how automated, modular solutions can:
- Accelerate development timelines
- Reduce operational complexity
- Improve manufacturing robustness
- Enhance end-to-end success across diverse modalities
